All Blocks
Our research
To meet pressing needs and tackle the pandemic, latest estimates show that around 1 million COVID-19 patients in LMICs require a total of over 2 million cylinders of oxygen per day—a number that continues to grow as COVID-19 case counts rise. Almost half of hospitals in LMICs have an inconsistent supply of medical oxygen or lack it entirely. Currently, approximately 50 LMICs are facing spikes in demand.

At the Access to Medicine Foundation, we are working for change with the medical gas industry, drawing on our experience moving the pharmaceutical industry on issues of access to medicines, vaccines and diagnostics.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec id elit non mi porta gravida at eget metus. Sed posuere consectetur est at lobortis. Cras mattis consectetur purus sit amet fermentum. Nulla vitae elit libero, a pharetra augue. Integer posuere erat a ante venenatis dapibus posuere velit aliquet. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor.
Sollicitudin Ridiculus Tortor Inceptos
Aenean Malesuada Amet Tellus
Elit Ultricies Vehicula Ipsum
Donec sed odio dui. Maecenas faucibus mollis interdum. Sed posuere consectetur est at lobortis. Integer posuere erat a ante venenatis dapibus posuere velit aliquet. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.
How can investors help?
To meet pressing needs and tackle the pandemic, latest estimates show that around 1 million COVID-19 patients in LMICs require a total of over 2 million cylinders of oxygen per day—a number that continues to grow as COVID-19 case counts rise. Almost half of hospitals in LMICs have an inconsistent supply of medical oxygen or lack it entirely. Currently, approximately 50 LMICs are facing spikes in demand.
At the Access to Medicine Foundation, we are working for change with the medical gas industry, drawing on our experience moving the pharmaceutical industry on issues of access to medicines, vaccines and diagnostics.
Three research programmes

Risus Etiam Fusce Quam
Jayasree and other panelists will explore the pharmaceutical industry’s 'access to care' strategies, the impact that COVID-19 has had on these strategies, and the opportunities available to investors to engage with companies on improving ESG (Environmental, Social and Governance) issues.
The virtual session will be moderated by Noemie de la Gorce, Vice President of ESG & Sustainability Research with J.P. Morgan.
The J.P. Morgan Global ESG Conference attracts some of the biggest players in the global ESG space. The 2022 event will focus on sustainability strategies, with a three-day agenda that covers key global, regional and sector themes; investment opportunities; and strategy outlook.
Jayasree joins the panel alongside:
Samir Shah, Global Head, Investor Relations, Novartis
Yo Takatsuki, Global Head of Investment Stewardship at JP Morgan Asset Management
The virtual session will be moderated by Noemie de la Gorce, Vice President of ESG & Sustainability Research with J.P. Morgan.
The J.P. Morgan Global ESG Conference attracts some of the biggest players in the global ESG space. The 2022 event will focus on sustainability strategies, with a three-day agenda that covers key global, regional and sector themes; investment opportunities; and strategy outlook.
Jayasree and other panelists will explore the pharmaceutical industry’s 'access to care' strategies, the impact that COVID-19 has had on these strategies, and the opportunities available to investors to engage with companies on improving ESG (Environmental, Social and Governance) issues.
The virtual session will be moderated by Noemie de la Gorce, Vice President of ESG & Sustainability Research with J.P. Morgan.